We scan new podcasts and send you the top 5 insights daily.
Carbone points to Keynote 407 five-year data where PD-L1-negative squamous tumors did so poorly that more control-arm patients were alive than treated patients. In his practice, he uses the 9LA dual immunotherapy regimen in that setting for those patients because long-term survival with chemoimmunotherapy is unimpressive.
Early Phase 3 trials like JAVELIN adding immunotherapy to chemoradiation failed to improve outcomes. However, subgroup analyses consistently showed a potential benefit in PD-L1 high-expressing patients, a crucial lesson that informed the design of subsequent, more successful studies.
The CheckMate 9LA regimen provides exceptional benefit to PD-L1 negative and squamous histology NSCLC patients. This is significant because these subgroups often respond poorly to other immunotherapy combinations, with Dr. Carbone noting some trials where the control arm outperformed pembrolizumab in these patients.
In frontline clinical trials for KRAS G12C NSCLC, combining olomorasib with pembrolizumab alone yielded a 90% response rate in patients with >50% PD-L1 expression. This surpassed the 78% rate seen when chemotherapy was added, suggesting a more targeted approach may be superior for this specific biomarker-defined subgroup.
In PD-L1 negative KRAS-mutated lung cancer, where standard immunotherapy is less effective, adding a CTLA-4 inhibitor can recover the immune response and create long-term survivors. This makes a triplet or quadruplet regimen the current optimal strategy for this challenging patient subgroup.
After standard immunotherapy biomarkers like PD-L1 and TMB proved ineffective in SCLC, the field shifted to a more direct approach. Novel therapies like the bispecific antibody tarlatumab target surface proteins such as DLL3, physically bridging immune cells to cancer cells without relying on predictive biomarkers.
Carbone says Checkmate 227 used dual immunotherapy without chemotherapy and had almost exactly the same efficacy, including in PD-L1-negative subsets. He questions whether adding chemotherapy, especially four cycles, adds much benefit, and he notes that patients in his experience often like having only two cycles.
Despite major advances in immunotherapy, patient selection remains crude compared to targeted therapies. PD-L1 is still the primary, yet imperfect, biomarker used. Dr. Carbone highlights an urgent need to develop better predictive biomarkers to customize immunotherapy regimens, as is standard for targeted agents.
Unlike existing standards that often require PD-L1 positivity for immunotherapy benefit, the Zanidatamab/Tisilzumab combination showed efficacy irrespective of PD-L1 status. This significantly expands first-line immunotherapy-based options to the minority of HER2+ patients who are PD-L1 negative and currently have fewer effective treatments.
Carbone says STK11 and KEAP1 mutations often mark immune-cold, PD-L1-negative tumors where dual immunotherapy may have extra activity. But he warns mutation testing is imperfect: many mutated STK11 tumors retain function, so high PD-L1 plus STK11 alone still pushes him toward single immunotherapy for first-line treatment.
Carbone says choosing between dervatremi and ipinevo is barely a choice because the dervatremi data are weaker, especially in squamous disease where the same signal is absent. Based on current evidence, he personally uses the ipinevo combination rather than dervatremi in his clinic for first-line NSCLC.